YU71102A - Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje - Google Patents

Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje

Info

Publication number
YU71102A
YU71102A YU71102A YUP71102A YU71102A YU 71102 A YU71102 A YU 71102A YU 71102 A YU71102 A YU 71102A YU P71102 A YUP71102 A YU P71102A YU 71102 A YU71102 A YU 71102A
Authority
YU
Yugoslavia
Prior art keywords
benzoic acid
acid amides
angiogenesis
inhibition
substituted benzoic
Prior art date
Application number
YU71102A
Other languages
English (en)
Inventor
Andreas Huth
Dieter Seidelmann
Karl-Heinz Thierauch
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of YU71102A publication Critical patent/YU71102A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Opisuju se supstituisani amidi benzoeve kiseline i njihova primena kao leka za tretiranje oboljenja, izazvanih perzistentnom angiogenezom kao i njihovi medjuproizvodi za proizvodnju amida benzoeve kiseline.[The invention relates to the substituted benzoic acid amides of the formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis, and to the intermediates thereof for producing the inventive benzoic acid amides.
YU71102A 2000-04-25 2001-04-24 Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje YU71102A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10021246A DE10021246A1 (de) 2000-04-25 2000-04-25 Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
YU71102A true YU71102A (sh) 2006-03-03

Family

ID=7640467

Family Applications (1)

Application Number Title Priority Date Filing Date
YU71102A YU71102A (sh) 2000-04-25 2001-04-24 Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje

Country Status (28)

Country Link
US (1) US20110009447A1 (sh)
EP (1) EP1280776B1 (sh)
JP (1) JP2004512259A (sh)
KR (1) KR100904101B1 (sh)
CN (1) CN1285578C (sh)
AT (1) ATE446288T1 (sh)
AU (2) AU5227201A (sh)
BG (1) BG107212A (sh)
BR (1) BR0110246A (sh)
CA (1) CA2406392C (sh)
CZ (1) CZ20023545A3 (sh)
DE (2) DE10021246A1 (sh)
EE (1) EE200200609A (sh)
ES (1) ES2334433T3 (sh)
HK (1) HK1056559A1 (sh)
HR (1) HRP20020933A2 (sh)
HU (1) HUP0300920A1 (sh)
IL (1) IL152292A0 (sh)
MX (1) MXPA02010559A (sh)
NO (1) NO325445B1 (sh)
NZ (1) NZ521681A (sh)
PL (1) PL358457A1 (sh)
RU (1) RU2353618C2 (sh)
SK (1) SK15222002A3 (sh)
UA (1) UA82980C2 (sh)
WO (1) WO2001081311A1 (sh)
YU (1) YU71102A (sh)
ZA (1) ZA200209494B (sh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
WO2005041684A2 (en) 2003-08-06 2005-05-12 Senomyx Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
TW200529812A (en) * 2003-12-26 2005-09-16 Chugai Pharmaceutical Co Ltd Benzamide derivatives
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
JP5200939B2 (ja) 2005-12-23 2013-06-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 二環式ヘテロアリール化合物
ES2640453T3 (es) 2006-04-21 2017-11-03 Senomyx, Inc. Procesos para preparar composiciones saborizantes sólidas
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JP5273037B2 (ja) 2006-05-08 2013-08-28 アリアド・ファーマシューティカルズ・インコーポレイテッド アセチレン性ヘテロアリール化合物
AU2007249926B8 (en) 2006-05-08 2013-11-07 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
JP2010510242A (ja) * 2006-11-16 2010-04-02 アラーガン、インコーポレイテッド キナーゼ阻害剤としてのスルホキシミン
EP2425840B1 (en) 2006-12-15 2015-04-08 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
CN101686665B (zh) 2007-04-20 2014-04-23 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
DK2346827T3 (da) 2008-08-27 2014-02-03 Leo Pharma As Pyridinderivater som VEGFR-2 receptor og proteintyrosinkinasehæmmere
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
BR112013013790A2 (pt) 2010-12-17 2016-09-13 Hoffmann La Roche compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
WO2015073864A1 (en) 2013-11-15 2015-05-21 The Wisar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use
EP3294705B1 (en) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
CN106740403A (zh) * 2017-03-21 2017-05-31 西北工业大学 一种液氮动力输出系统及混合动力冷链运输车
CN112543634A (zh) 2018-05-17 2021-03-23 威斯达研究所 Ebna1抑制剂晶体形式及其制备和使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643265C3 (de) * 1967-12-22 1978-08-31 C.H. Boehringer Sohn, 6507 Ingelheim Kernsubstituierte 2-Aminomethylbenzhydrole, Verfahren zu deren Herstellung und Arzneimittel auf der Basis dieser Verbindungen
JPH02218654A (ja) * 1988-10-12 1990-08-31 Ono Pharmaceut Co Ltd 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
US5863455A (en) * 1997-07-14 1999-01-26 Abb Power T&D Company Inc. Colloidal insulating and cooling fluid
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
WO2000002871A1 (en) * 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
JP2002523459A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤
IL142583A0 (en) * 1998-11-06 2002-03-10 Basf Ag Inhibition of the formation of vascular hyperpermeability
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo

Also Published As

Publication number Publication date
NO20025102L (no) 2002-12-17
DE10021246A1 (de) 2001-10-31
CN1426396A (zh) 2003-06-25
BG107212A (bg) 2003-05-30
CZ20023545A3 (cs) 2003-02-12
WO2001081311A1 (de) 2001-11-01
PL358457A1 (en) 2004-08-09
EP1280776B1 (de) 2009-10-21
CA2406392C (en) 2011-08-30
NZ521681A (en) 2006-03-31
HUP0300920A1 (hu) 2003-07-28
KR100904101B1 (ko) 2009-06-24
NO325445B1 (no) 2008-05-05
AU5227201A (en) 2001-11-07
CN1285578C (zh) 2006-11-22
AU2001252272B2 (en) 2007-03-29
EE200200609A (et) 2004-04-15
SK15222002A3 (sk) 2003-06-03
UA82980C2 (ru) 2008-06-10
HRP20020933A2 (en) 2005-02-28
ATE446288T1 (de) 2009-11-15
HK1056559A1 (en) 2004-02-20
EP1280776A1 (de) 2003-02-05
ES2334433T3 (es) 2010-03-10
CA2406392A1 (en) 2001-11-01
US20110009447A1 (en) 2011-01-13
ZA200209494B (en) 2004-07-14
BR0110246A (pt) 2003-03-05
JP2004512259A (ja) 2004-04-22
MXPA02010559A (es) 2003-03-10
DE50115189D1 (de) 2009-12-03
RU2353618C2 (ru) 2009-04-27
NO20025102D0 (no) 2002-10-24
KR20020093946A (ko) 2002-12-16
IL152292A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
YU71102A (sh) Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje
NL300933I2 (nl) Letermovir
YU31801A (sh) Amidi antranilne kiseline i njihova upotreba kao leka
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
RS60503A (en) Substituted alkylamine derivatives and methods of use
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
BG105513A (en) Substituted benzopyran analogs for the treatment of inflammation
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
MXPA04002405A (es) Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
SE0100569D0 (sv) New compounds
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
TW200505865A (en) Compounds useful for the treatment of diseases
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
RS20060054A (en) Substituted furochromene compounds of antiinflammatory action
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
DE60209122D1 (de) Bernsteinsäurederivate
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
WO2002030874A3 (en) Aliphatic, cyclic amino carboxylic acids as integrin antagonists